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INTRODUCTION
Campylobacter is a major cause of acute bacterial diarrhea in
humans worldwide (3). The incidence of human campylobac-
teriosis increased exponentially during the last decade of the
20th century (183), although part of this increase can be at-
tributed to better detection of Campylobacter and better diag-
nosis. At the start of the 21st century, this increase has stopped,
as shown by data for the total number of Campylobacter cases
in the European Union until 2003 (Fig. 1). In humans, the
clinical symptoms of campylobacteriosis are watery or bloody
diarrhea, abdominal cramps, and nausea (151). In a small
subgroup of patients, the acute phase is followed by serious
sequelae: Guillain-Barre´ syndrome (GBS) and reactive arthri-
tis (78, 86). Acute diarrhea, Campylobacter-related mortality,
and residual effects of GBS are the main determinants con-
tributing to this disease burden (79). Campylobacteriosis in
humans is induced mainly by Campylobacter jejuni (about 90%
of cases), and the remaining fraction is induced predominantly
by Campylobacter coli. Campylobacter is part of the normal
intestinal flora of birds, and humans are not the reservoir for
infection. As a result, poultry is a major source of infection.
The estimation of incidence of Campylobacter enteritis in the
population is usually based on confirmed cases corrected for
several factors like the proportion of patients consulting a
physician and the number of this group submitting a stool
sample for Campylobacter isolation. Because the infection is
usually self-limiting, the true population incidence is estimated
to be 8 to 30 times higher than confirmed cases, depending on
the country (148, 166, 179).
The estimated rate of campylobacteriosis (number of cases/
100,000 individuals) differs strongly around the world, with
New Zealand as the country with the highest rate (396/100,000
persons), compared to, e.g., the United States (reported as
being 12.7/100,000 persons by FoodNet in 2005) (13, 44). The
excessive rate in New Zealand seems to be real, but it remains
unexplained. New Zealand’s campylobacteriosis epidemic
reached a new peak in May 2006, with the annualized national
notification rate exceeding 400 per 100,000 individuals for the
first time, the highest national rate reported in the literature
(12). Differences among countries should be considered with
care, as surveillance and reporting systems may differ markedly
from country to country. For example, differences among
countries within the European Union have been reported: the
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Czech Republic reported an incidence of 303/100,000 individ-
uals, whereas other countries did not report a single case (Ta-
ble 1). It is highly unlikely that these differences are real. There
is little information about mortality due to campylobacteriosis.
It is estimated that in The Netherlands (population of about
16,000,000 individuals), with an estimated incidence of campy-
lobacteriosis of about 59,000 cases, around 25 people die of
Campylobacter infection every year (92). Most Campylobacter
infections occur as sporadic cases, and outbreaks are rare or
are not recognized. The few reported outbreaks are most com-
monly associated with raw milk or water (57, 98, 139, 153, 159).
This is surprising for a food-borne pathogen, although it is
known that the dose of Campylobacter present in food is highly
variable. Better monitoring of possible outbreaks is essential to
increase our understanding of the epidemiology of campy-
lobacteriosis in humans. Such outbreaks also provide a unique
opportunity to study host responses to Campylobacter, for in-
stance, by measuring immune parameters in cases and exposed
controls. Although poultry is a major source of infection, it is
estimated that in The Netherlands, only 20% to 40% of all
laboratory-confirmed cases are attributable to the consump-
tion of undercooked chicken (80). This percentage is in agree-
ment with estimates from Belgium (40%), where the with-
drawal of poultry meat from the market following dioxin
contamination of chicken feed resulted in a clear decline in
human campylobacteriosis incidences (171). Other risk factors
include drinking raw milk or contaminated water, traveling
abroad, and contact with pets. However, a large proportion of
all infections (i.e., approximately 50%) cannot be attributed to
any of the known risk factors, indicating that other sources
exist. Although humans are also most probably exposed to
Campylobacter from currently unknown sources, the exposure
of humans to poultry meat is the best-understood source, and
consequently, most effort is put into Campylobacter control
strategies along the poultry meat production chain. However,
extensive control strategies with the overall aim to reduce
Campylobacter contamination on poultry meat have been only
partly successful. We conclude that humans will be continu-
ously exposed to Campylobacter from poultry meat, from
sources where interventions cannot be implemented (contact
with pets), and from unknown sources. As exposure will not be
equally distributed in the population (pet owners and profes-
sionally exposed humans) and the population will not be
equally susceptible (children and the elderly), we urgently need
more understanding of the pathogen-host interaction. Only
with this knowledge can science-based risk assessments be per-
formed and science-based intervention strategies be devel-
oped. Since the exposure of the population to Campylobacter
cannot be prevented, it is crucial to understand the risks in-
volved with exposure and to identify groups in the population
that are more at risk. Currently available risk assessment mod-
els do not explicitly take into account that individuals display
differential susceptibility to infection. A better understanding
of the pathogenic mechanisms of Campylobacter and, impor-
tantly, of the host factors involved in the defense against
Campylobacter infection may lead to the identification of risk
factors in the population. It is conceivable that the efficacy of
some of these host factors in the defense against Campy-
lobacter is genetically determined. Studying these host factors
could contribute both to novel intervention strategies and to
the development of more realistic risk assessment models that
incorporate such host susceptibility factors and/or more tar-
geted intervention strategies.
FIG. 1. Total number of confirmed Campylobacter cases in the Eu-
ropean Union until 2003. Data after 2003 are not shown because
several new European Union (EU) member states with a high reported
incidence of campylobacteriosis joined the European Union (Table 1).
TABLE 1. Reported campylobacteriosis cases in humans and
incidence of cases in Europe in 2005a
Country No. of confirmedcases
No. of confirmed
cases/100,000
individuals
Austria 5,065 61.7
Belgium 6,879 65.8
Cyprus 0 0
Czech Republic 30,268 302.7
Denmark 3,677 68
Estonia 124 9.2
Finland 4,002 76.4
France 2,049 3.3
Germany 62,114 75.3
Greece —b —
Hungary 8,288 82.1
Ireland 1,794 43.7
Italy — —
Latvia 0 0
Lithuania 694 20.3
Luxembourg 194 42.6
Malta 91 22.6
The Netherlands 3,761 46.2
Poland 47 0.1
Portugal — —
Slovakia 2,204 40.9
Slovenia 0 0
Spain 5,513 12.8
Sweden 5,969 66.2
United Kingdom 52,686 88.5
European Union total 195,419 51.6
Iceland 128 43.6
Norway 2,631 57.1
Total 198,178 51.7
a Adapted from reference 54.
b —, no cases reported.
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The scope of this review is to summarize available data on
host factors involved in the response to Campylobacter jejuni
and how these factors can increase our understanding of host-
pathogen interactions. In other diseases, the majority of such
factors are elucidated by studying infection in murine models
with well-defined genetic mutations in host defense mecha-
nisms. However, Campylobacter does not induce disease in
wild-type mice, and rodent models that mimic human disease
have been lacking. Recent progress in the generation of gene-
deleted mice has now resulted in the in the development of
murine models, which have contributed to our understanding
of the defense against Campylobacter and will be valuable for
further studying host responses to Campylobacter infection
(discussed below) (63, 106, 177).
This study was aimed at summarizing the current under-
standing of host mechanisms involved in the defense against
Campylobacter by evaluating data available from three sources:
(i) epidemiological observations, (ii) observations of patients,
and (iii) experimental observation including observations of
animal models and human volunteer studies.
PATHOLOGY AND PATHOPHYSIOLOGY OF
CAMPYLOBACTER INFECTION
Humans are orally exposed to Campylobacter. During pas-
sage through the acidic environment of the stomach, a large
proportion of the ingested dose may be killed, depending on
the buffering capacity of the food. The remaining bacteria can
survive and are able to adhere to intestinal epithelial cells or to
the mucus overlying these cells and replicate in the intestine. In
infected individuals, this can result either in asymptomatic
colonization status, i.e., bacteria are present in the intestine
but do not induce disease (41, 45), or in diarrheal illness.
Campylobacter is highly infectious, and infective doses as low as
500 to 800 CFU have been reported (23, 140). A probability of
2% for any CFU to establish infection was calculated in a
volunteer experiment (23, 160).
The colonization status in humans is reminiscent of that
found in various rodents, mammals, and birds. Chickens can be
colonized with as many as 109 CFU C. jejuni per gram cecal
contents (43), and colonized mice can shed up to 106 CFU per
mg feces (18). Studies of children in developing countries have
shown that rates of asymptomatic carriage of Campylobacter in
children are around 15% (108, 131), suggesting that some
acquired immunity is induced from multiple exposures during
early childhood. Wheeler et al. reported a rate of asymptom-
atic carriage of 0.7% in a population study involving adults in
the United Kingdom (179). This indicates that bacterial clear-
ance is inefficient and raises questions about how effective the
immune response is in clearing all bacteria. The difference
between humans and rodents is that in the latter, Campy-
lobacter fails to cause diarrheal illness, indicating that animals
lack specific factors, e.g., receptors, necessary for Campy-
lobacter to cause disease, that effective immune mechanisms
are present in animals that prevent the development of clinical
disease, or that disease-causing host responses are absent.
After colonization of the intestine, clinical disease may oc-
cur. Based on clinical syndromes found in patients, two mech-
anisms by which Campylobacter can induce disease were pos-
tulated (85): (i) adherence of Campylobacter to the intestine
and the production of toxins (173), which alter the fluid re-
sorption capacity of the intestine, resulting in secretory diar-
rhea, and (ii) bacterial invasion and replication within the
intestinal mucosa accompanied by an inflammatory response
resulting in blood-containing, inflammatory diarrhea.
In immunocompetent individuals, disease is restricted to the
intestine, although bacteremia has been observed. The re-
ported incidence for bacteremia ranges from 1.5 to 8 in 1,000
individuals (89, 152). Occasionally, passage through the intes-
tinal mucosa and migration to extraintestinal sites via the
lymphatic system result in systemic disease. However, it is
important to note that systemic disease is very rare in immu-
nocompetent individuals.
Clinical disease is characterized by acute diarrhea accompa-
nied by intense abdominal pain. Campylobacteriosis is an in-
flammatory enteritis that is initially found in the small bowel
and later affects the colon and the rectum (23). The incubation
time is 1 to 7 days (mean, 3 days), which is longer than the
incubation times of most other intestinal pathogens. The diar-
rhea can be either watery or, in almost one-third of the cases,
bloody (79, 151, 174), indicating that the extents of intestinal
inflammation vary among individuals. Inflammatory diarrhea
points to a role for polymorphonuclear leukocytes (PMN) in
pathology and suggests that infection can lead to extensive
intestinal damage either as a direct result of bacterial toxins or
as a result of the inflammatory infiltrate. It has been shown that
this is in part related to differences in properties of the infect-
ing strain (23, 60). Usually, diarrhea begins to ease after 3 to 4
days, but Campylobacter can be found in the feces for several
weeks (89). Using a highly sensitive culture-based detection
assay, Kapperud et al. observed carriage in 16% of individuals
during convalescence, with a median carriage time of 31 days
(89). Although a large proportion of the patients feel nau-
seous, only about 15% of patients vomit (151, 174). In 30% of
patients, the disease does not start with diarrhea but with a
prodrome of influenza virus-like symptoms such as fever, head-
ache, dizziness, and myalgia (reviewed in reference 151), indi-
cating that there is some systemic, probably immune-mediated,
effect of local infection. Patients that suffer from such a pro-
drome tend to have more serious disease than patients without
the prodrome, but the reasons for this are currently unknown
(reviewed in reference 151).
In most immunocompetent individuals, campylobacteriosis
is a self-limiting disease, and treatment with antimicrobials
reduces the period of fecal shedding but does not have a large
impact on the duration of disease symptoms (4, 105, 180).
However, when given early, some clinical benefit has been
observed (126, 147). When patients suffer from recurrent or
systemic Campylobacter infection, antimicrobial treatment is
indicated. However, an increase in antimicrobial resistance,
especially fluoroquinolone resistance, in both human and ani-
mal isolates has been observed over the last decade (93, 167).
SEQUELAE OF CAMPYLOBACTER INFECTION
While Campylobacter enteritis is usually self-limiting and
the disease is resolved within 1 week in the majority of cases,
some individuals develop sequelae after the acute phase.
Approximately 1 in 1,000 infected individuals develops GBS,
a serious autoimmune-mediated neurological disorder that
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can cause symptoms ranging from weakness of extremities
to complete paralysis and respiratory insufficiency (reviewed
in reference 116). Mortality rates due to GBS in the indus-
trialized world are 2% to 3%, although the majority of
patients recover completely within 6 to 12 months (182). In
The Netherlands, the health burden for Campylobacter-as-
sociated GBS was estimated at 164 disability-adjusted life
years in 2004 (92). Miller-Fisher syndrome, a subvariant of
GBS that affects predominantly the nerves that govern eye
movement, has also been associated with Campylobacter in-
fection (138, 187).
GBS is thought to occur because of molecular mimicry
between lipooligosaccharide, a component of the cell enve-
lope of Campylobacter, and sugar moieties on nerve ganglio-
sides (6, 9, 117, 189). Antibodies that are raised during
infection with Campylobacter serotypes containing such gan-
glioside mimics can cross-react with gangliosides in some
individuals, leading to the demyelinization of nerves and the
degeneration of axons (for a review, see reference 181).
Evidence suggests that both strain properties and host prop-
erties play a role in determining the development of GBS.
For instance, serotype HS:19 was overrepresented in Japa-
nese GBS patients (97, 188) but not in United Kingdom
patients (138), indicating a role for host factors. In addition,
although ganglioside-mimicking structures were found more
frequently in neuropathy-associated Campylobacter strains
than in strains isolated from patients with diarrhea (7),
strains that contain these ganglioside mimics are also often
found in patients with uncomplicated enteritis (117). Re-
cently, it was shown that specific types of the lipooligosac-
charide biosynthesis gene locus are important for the ex-
pression of ganglioside mimics and the induction of
antiganglioside antibodies (73). Taken together, these data
suggest that although the presence of ganglioside mimics is
important, it is not the only factor that determines the
development of GBS. Currently, the role of host genetic
factors in determining if GBS evolves upon infection with
Campylobacter strains with ganglioside mimics is studied
extensively. A complete review of all factors associated with
the development of GBS is beyond the scope of this review
(for reviews on this issue, see references 86 and 116), but
some of the genetic factors that have recently been associ-
ated with the development or severity of GBS are listed in
Table 2. Not only Campylobacter but also other pathogens
have been associated with the development of GBS. How-
ever, most of the genetic studies on susceptibility to GBS are
performed with GBS patients, irrespective of the causative
pathogen. Therefore, host factors that determine suscepti-
bility to GBS may shed more light on processes involved in
breaking tolerance to self-antigens than on susceptibility to
diarrheal illness. Further studies are needed to investigate if
similar mechanisms are also involved in determining suscep-
tibility to Campylobacter-induced diarrhea.
Other immune-mediated sequelae of Campylobacter infec-
tion include reactive arthritis (22, 101, 164) and Reiter syn-
drome, an inflammatory disease with either conjunctival or
urethral inflammation (91). Symptoms of reactive arthritis usu-
ally occur around 14 days after infection (range, 3 days to 6
weeks), and the estimated incidence of reactive arthritis in
community outbreaks ranges from 0 to 7% (53, 92, 109, 111).
Reactive arthritis is associated with HLA-B27, and various
gastrointestinal pathogens can lead to its development (149).
The symptoms appear to be similar regardless of the associated
bacterial infection, indicating a role for factors common to a
range of pathogens (149). Usually, these joint symptoms re-
solve completely. There are also a few case reports of Campy-
lobacter-associated hemolytic-uremic syndrome, which is a
well-known sequela of infection with verocytotoxin (Shiga toxin)-
producing Escherichia coli strains (151). Campylobacter strains
have also been isolated from patients with inflammatory bowel
disease (IBD) such as Crohn’s disease and have been associ-
ated with flare-ups of IBD, although a causal link between the
two is still under debate (21, 67, 178). A recent registry-based
study in Denmark revealed very strong associations between
Campylobacter infection and the development of IBD, but this
association still needs to be confirmed (81). A link between
infection by enteric pathogens, including Campylobacter, and
irritable bowel syndrome was also observed (52, 81, 156, 162).
These enteric infections result in damage to the mucosa and
disruption of the native gut flora, which could lead to pro-
longed bowel dysfunction (156). In a small-scale patient study,
a correlation between persistently changed bowel habits fol-
lowing Campylobacter infection and the in vitro toxicity of the
infecting strain was observed (162). There is laboratory evi-
dence for a number of Campylobacter toxins (reviewed in ref-
erence 173), although, to date, the only toxin cloned, se-
quenced, and identified from genome sequences is cytolethal
distending toxin (CDT), and no direct role for this toxin in the
etiology of irritable bowel syndrome has so far been demon-
strated.
TABLE 2. Genetic factors studied in association with the
development of GBS or Campylobacter-associated GBS
Gene studied Association withGBS
Association with
Campylobacter-induced
GBSa
Reference
MMP9 Yes, severity NS 68
TNFA Yes, severity NS 68
IL-10 No NS 68
IL-10 No NS 68
CD1 Yes, incidence NS 37
MBL2 Yes, severity NS 70
HLA class II Yes, severity NS 71
HLA-DRB1 No Nonsignificant
association (trend)
103
HLA B54 Yes, incidence Yes, incidence 95
HLA-Cw1 No Yes, incidence 95
FCGR2A Yes, incidence/
severity
NS 165
FCGR3A No NS 165
FCGR3B No NS 165
FCGR3B Yes, severity NS 170
FCGR3B Yes, severity NS 169
IL-10 Yes, incidence NS 115
FAS/CD95 Yes, GM1
antibodies
NS 69
CD14 No No 56
TLR4 No No 56
APOE No NS 136
TNFA NS Yes, incidence 102
a NS, not studied.
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ROLE OF HUMAN IMMUNITY IN
CAMPYLOBACTER DISEASE
Epidemiological Observations
Many Campylobacter types are encountered by the human
host, but these types will probably lead to disease in only a
minority of cases. Apparently, not every encounter results in
the development of disease. Both bacterial virulence factors
and host susceptibility factors are thought be involved in de-
termining if disease develops. In addition, environmental fac-
tors such as the matrix in which Campylobacter is consumed
and the acidity of the stomach are involved (Fig. 2). Exposure
is obviously a critical factor in the development of disease, and
although hypothetical, a higher incidence in rural areas than in
urban areas is often explained as a result of higher exposure in
rural areas (58, 74, 161). In accordance with this hypothesis, it
was found that in rural areas, like in developing countries, the
age distribution was shifted to younger ages than in urban
areas (58, 74). However, it is believed that frequent exposure
can also result in the development of a certain level of basal
immunity to Campylobacter (see also the section on developing
countries below). Such responses probably do not lead to pro-
tection against a broad range of serotypes. Epidemiological
support for this assumption came from data reported recently
by Miller et al., which showed that infections with common and
rare types of Campylobacter occur in different age groups,
where the rare types are overrepresented in the older age
groups (110). This indicates that basal immunity to commonly
encountered serotypes occurs but that a broad level of protec-
tion against all serotypes does not develop. However, since
even rare serotypes will have structures in common with com-
mon serotypes, this observation warrants further investigation.
The fact that not every individual displays the same suscep-
tibility to Campylobacter infection can also be concluded from
a range of other epidemiological observations. When outbreak
data are analyzed, it is clear that not every person exposed to
a certain dose of Campylobacter either will be colonized or will
develop disease. These differences can be associated with non-
specific factors such as stomach content and, related to this, the
acidity of the stomach. Indeed, the use of proton pump inhib-
itors in the month prior to Campylobacter infection was shown
to increase the risk of clinical disease by as much as 10-fold
(121). However, innate and specific immune factors may also
play a role in determining the susceptibility of an individual to
Campylobacter infection.
In developing countries, the incidence of Campylobacter en-
teritis peaks in children and declines clearly after childhood. In
industrialized countries, Campylobacter disease peaks in chil-
dren as well, but the steep decline does not occur but peaks
again at a young adult age and declines gradually afterwards
(66). The course of disease is generally more severe; i.e., in-
fection is more often accompanied by bloody diarrhea (64,
127). In addition, it is thought that after the peak in childhood,
in the developing world, asymptomatic infections are more
common than in the industrialized world. In the developing
world, children are frequently exposed to Campylobacter infec-
tion early in life due to contaminated drinking water and close
contact with animals and therefore have elevated Campy-
lobacter-specific antibody levels compared to those of children
in the United States (25, 30, 107). In Thailand, bloody diarrhea
was most often associated with disease in the first year of life,
suggesting an association with primary infection (158). How-
ever, the occurrence of asymptomatic carriage in developing
(and industrialized) countries (127) suggests that any immunity
acquired following exposure protects against disease rather
than colonization.
Observations of abattoir workers in Sweden (41, 45) support
the idea that frequent exposure to Campylobacter induces pro-
tection against disease. Recently employed and presumably
immunologically naı¨ve workers suffered many more episodes
of Campylobacter diarrhea than workers who were employed
for many years. Consistent with the observation in the devel-
oping world, the latter group of workers regularly succumbed
to asymptomatic infection with Campylobacter (41, 45). These
data indicate that humans can develop immunity to Campy-
lobacter disease, but probably not to colonization, although this
immunity seems to be short-lived, and data suggest that fre-
quent exposure to multiple serotypes/immunotypes may be
necessary to boost this immunity.
In conclusion, these epidemiological observations indicate
that differences in immune responses are observed in various
individuals and due to differences in exposure, but to what
extent they are determined by host factors, or if they are
related to frequency of exposure, remains to be established. It
is also clear that the acidity of the stomach is a crucial early
defense mechanism against Campylobacter, although this is not
specific for Campylobacter and has also been observed for
other pathogens such as Salmonella (50, 51).
Observations of Patients
Certain groups of patients are more susceptible to Campy-
lobacter disease than the general population. Two groups of
patients that are particularly susceptible are those with hypo-
or agammaglobulinemia, who suffer from defects in humoral
immunity, and those with AIDS, who suffer from a defect in
cell-mediated immunity (134, 151). Such patients often expe-
rience more severe clinical disease that is more frequently
accompanied by bacteremia. The incidence of Campylobacter
disease in AIDS patients was shown to be 40-fold higher than
that in the general population (155). Chronic carriage and
FIG. 2. Schematic representation of host-pathogen interactions in
campylobacteriosis. Pathogen-host encounters in a certain environ-
ment can either lead to infection or not. Infected individuals can then
remain asymptomatic or go on to develop disease. To what extent this
leads to the induction of protective immunity is currently unknown.
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recurrent infection are also more frequently found in these
highly susceptible patients, and repeated courses of antimicro-
bial treatment are often indicated. Severe Campylobacter in-
fection is found in AIDS patients both in the industrialized
world and in developing countries (47).
The genetic causes of the above-mentioned immunoglobulin
deficiencies can be a result of a whole range of primary or
acquired immune deficiencies (reviewed in reference 61).
These patients are susceptible not only to Campylobacter but
also to a whole range of other pathogens. The most frequent
cause of hypogammaglobulinemia is common variable immu-
nodeficiency, a heterogeneous disease that occurs in approxi-
mately 1:50,000 to 1:100,000 Caucasians. Mutations in the gene
encoding ICOS, an inducible T-cell costimulatormolecule es-
sential for proper B-cell activation, is one genetic cause of
common variable immunodeficiency (75). Agammaglobuline-
mia is a very rare but serious recessive X-linked disease that is
usually caused by a mutation in Bruton tyrosine kinase, an
enzyme essential for B-cell maturation (163, 172).
From those observations, it can be concluded that various
(genetically determined) immune-related host factors are in-
volved in susceptibility to Campylobacter infection, although it
has to be taken into account that all the above-mentioned
diseases lead to severe immune defects resulting in suscepti-
bility to a whole range of pathogens. Since hypogammaglobu-
linemic/agammaglobulinemic patients and AIDS patients are
subject to prolonged symptoms and repeated infection, these
data do suggest a role for humoral and T-cell immunity in
limiting the infection (8, 134). However, they do not explain
the susceptibility specifically to Campylobacter infection, be-
cause such patients are also susceptible to a whole range of
other pathogens. This is in sharp contrast to studies of patients
with enhanced susceptibility to Salmonella and Mycobacterium
spp., where “the human model” clearly points to specific host
mechanisms that are involved in the defense against these
pathogens (38, 128).
Innate Immunity to Campylobacter
Upon ingestion, Campylobacter has to first pass the acidic
environment of the stomach. This is clearly an effective barrier,
since patients that use proton pump inhibitors are more sus-
ceptible to Campylobacter infection (51, 121). In the intestine,
Campylobacter has evolved strategies to circumvent the induc-
tion of innate immunity. For instance, Toll-like receptor 5
(TLR5), the pattern recognition receptor for flagellin, is not
stimulated by Campylobacter due to the structure of its flagellin
(5, 175). Also, TLR9, the receptor for CpG dinucleotides, is
not efficiently stimulated (49). However, mice deficient in
MyD88, a crucial signaling molecule downstream of TLRs,
have recently been shown to be susceptible to Campylobacter
infection (177), indicating that TLR pathways are important
for the defense against disease. This is confirmed by the fact
that NF-B-regulated transcription is readily activated in in
vitro models (88) and apparently necessary for defense, since
NF-B-gene deleted mice display enhanced susceptibility to
infection (63). So although Campylobacter can circumvent the
activation of innate immunity via TLR5 and TLR9, innate
immune mechanisms are essential for host defense. Recently,
it was shown that innate responses to Campylobacter are at
least partly mediated by the intracellular pattern recognition
receptor NOD1 (190) and that natural resistance-associated
macrophage protein, a gene involved in macrophage activa-
tion, also plays a role in susceptibility to campylobacteriosis
(177).
Fucosylated sugars present in breast milk were shown to
inhibit the in vitro and in vivo binding of Campylobacter to the
intestinal mucosa and inhibit diarrhea (28, 112, 143). In addi-
tion, C. jejuni is serum sensitive, highlighting the importance of
complement-mediated killing (28). The role of PMN-mediated
killing of opsonized bacteria was shown to be variable (133). As
discussed below (see “In Vitro Models of Infection”), a wide
range of studies have shown that Campylobacter is able to
induce a proinflammatory response. Whether a strong proin-
flammatory response is also induced in vivo is still under study.
Humoral Immunity to Campylobacter
Most people infected with Campylobacter develop humoral
responses to a number of Campylobacter antigens. Experimen-
tal studies have shown the specificities and kinetics of immune
responses during infection of primates and human volunteers
(24, 145). In humans, circulating antibodies are first detectable
6 to 7 days after the onset of illness and rise rapidly shortly
afterwards (reviewed in reference 124). Specific serum immu-
noglobulin A (IgA) levels peak 7 to 10 days after the onset of
symptoms. Specific serum IgG levels peak after 3 to 4 weeks.
Serum IgA levels decline rapidly after the onset of illness,
whereas IgM and especially IgG levels remain high for a longer
time (26, 40, 157). Antibody decay profiles for patients show
that serum IgA levels declined to baseline levels within 2.5
months after infection (157), with a similar trend for salivary
IgA levels (40). Serum and salivary IgG levels declined within
4.5 months after acute infection but remained elevated for
prolonged periods of time, although large individual variation
was apparent (40, 157). It is obviously more difficult to assess
the kinetics of local, mucosal responses to infection, so there
are fewer data on the subject. Specific antibodies have been
detected in feces and urine during natural infection (99), and
specific secretory IgA was detected in jejunal fluid from vol-
unteer infections (24).
Antibody specificity studies have identified a number of
Campylobacter antigens recognized during infection. Not sur-
prisingly, many of the features highlighted as potential viru-
lence factors, and which are on the cell surface, are immuno-
genic. A major, immunodominant antigen of Campylobacter is
flagellin, the subunit protein of flagella (118, 119).
A number of other proteins, including major outer mem-
brane proteins, have also been identified as being immuno-
genic, although their natures and roles are often unknown. The
periplasmic/membrane-associated proteins PEB1 (28 kDa)
and PEB3 (30 kDa) were found to be strongly immunogenic;
15/19 convalescent-phase sera were found to recognize them in
enzyme-linked immunosorbent assays (132). Panigrahi et al.
(129) identified a number of proteins that were expressed, or
overexpressed, only in vivo. Two of these, with molecular
masses of 47 and 84 kDa, were found to elicit strong serum IgG
responses in humans following infection, including sera from
volunteers who were immune to C. jejuni infection when re-
challenged. Capsular polysaccharide antigens, the basis of the
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Penner serotyping scheme, are also immunogenic, eliciting
both type-specific and cross-reactive responses (114, 144). The
CDT produced by Campylobacter is also immunogenic in hu-
man infections, eliciting toxin-neutralizing antibodies (1). In-
terestingly, chickens do not develop neutralizing antibodies
against CDT, indicating host specificity in the immune re-
sponse to Campylobacter (1). Until we know the true correlates
of protective immunity to campylobacteriosis, the role of these
antibodies in conferring protective immunity is difficult to es-
tablish.
Role of Humoral Immunity in Protection
As described above, epidemiological data indicate that hu-
moral immunity is crucial for the development of protection
against Campylobacter disease. Consistent with this, patients
with defects in immunoglobulin production are more suscep-
tible to infection. The first humoral immune mechanism en-
countered by Campylobacter during infection is secretory IgA
(sIgA), and various studies have shown that the presence of
Campylobacter-specific sIgA and serum IgA correlates with
protection against disease (108, 142). Also, studies of breastfed
infants point to a protective role of sIgA against infection. In a
Mexican study where children were monitored from birth to
the age of 2 years, breastfeeding decreased the incidence of
diarrhea caused by C. jejuni, and this decrease was associated
with the presence of Campylobacter-specific sIgA in breast milk
(142). Breast milk containing sIgA against Campylobacter
flagellin proteins also decreased the incidence of Campy-
lobacter-induced diarrhea in babies. In addition, there is also a
description of one immunocompromised patient in which oral
sIgA administration resolved a recurrent Campylobacter infec-
tion (77).
Even though all these data point to an important role for
sIgA in protection against Campylobacter disease, it is surpris-
ing that there are no studies to suggest that patients with IgA
deficiency (35) are more susceptible to Campylobacter infec-
tion than the general population. IgA deficiency is the most
common primary immunodeficiency found in humans, and it is
estimated to occur at a frequency of 1:333 to 1:700 in Cauca-
sians (46). The genetic cause underlying IgA deficiency is un-
known, but from these data, it can be concluded that other
compensatory mechanisms are activated in the absence of IgA
and that IgA is probably important but not crucial for the host
defense against Campylobacter. In addition, the presence of
sIgA in a mother’s breast milk is probably accompanied by the
transplacental transfer of maternal IgG to the baby during
pregnancy, indicating that effects observed in breastfeeding
studies could also be related to IgG.
A protective role of IgM against Campylobacter infection
was suggested by the observation that in hypo- or agamma-
globulinemic patients who suffered from severe Campylobacter
infection, the infusion of a pentaglobin preparation, which
contained Campylobacter-specific IgM, completely resolved the
infection, whereas immunoglobulin preparations that con-
tained only IgG did not (31). Although this observation was
made for a few of patients, it does point to a role for IgM in
protection. This also fits with the assumption that increased
IgM production is one of the general immune compensation
mechanisms in patients with IgA deficiency. In addition, there
is an active secretion mechanism for IgM at mucosal surfaces
(34), and IgM antibodies can fix complement almost 200 times
more efficiently than IgG (32). In contrast to Campylobacter-
specific IgG, IgM can also enhance reactive oxygen interme-
diate production and bactericidal activity of PMN (10).
From the finding that patients with hypo- or agammaglob-
ulinemia are more susceptible to Campylobacter infection, it is
clear that IgG also plays an important role in protection
against disease. IgG levels remain high for a longer time than
do IgA and IgM levels after infection (40, 157). Chronic raw
milk consumers have high IgG levels and seem to be protected
against Campylobacter disease (27). Similarly, children in de-
veloping countries develop IgG responses very early in life and
are then protected against bloody diarrhea (25, 30), indicating
that IgG is also involved in protection against disease.
Cellular Immunity
Systemic and recurrent Campylobacter infections in patients
with human immunodeficiency virus or AIDS, who have a
significant reduction in the level of CD4 T cells, point to an
important role of cell-mediated immunity in the defense
against Campylobacter infection, although B-cell responses and
antibody production can also be impaired in AIDS patients.
There has been one report on the cellular immunity of a
patient who suffered from severe Campylobacter infection. Pe-
ripheral blood mononuclear cells of this patient proliferated in
response to the homologous strain (19). In addition, the rapid
induction of proinflammatory cytokine production was ob-
served in the serum of this patient. Recently, both viable and
killed Campylobacter preparations were shown to induce the
maturation of dendritic cells in vitro and the induction of
various proinflammatory cytokines (83), indicating that
Campylobacter induces both innate and specific cell-mediated
immune responses.
There are also indications that Campylobacter extracts in-
duce the in vitro expansion of / T cells obtained from healthy
controls. This cell type has been implicated in mucosal immune
responses. These cells respond to nonprotein components in
the Campylobacter extract (168). Since it is not known whether
/ T-cell expansion also occurs in vivo, the significance of this
observation in relation to protection against Campylobacter
infection is unknown.
Although cell-mediated immunity appears to be important
in the defense against Campylobacter, the available data do not
point to specific candidate host factors that could be studied in
humans.
LESSONS LEARNED FROM EXPERIMENTAL INFECTION
In Vitro Models of Infection
Study of the mechanisms of Campylobacter infection and
pathogenesis is complicated by the lack of simple animal mod-
els that mimic human infection. In vitro cell culture methods
provide a useful alternative to investigate the interactions be-
tween Campylobacter and the host epithelium that occur dur-
ing infection. In the genomics era, there is an increasing use of
in vitro cell culture techniques to determine the potential role
of different genes in infection and pathogenesis. In vitro stud-
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ies on host-pathogen interactions often use cells of epithelial
origin. These can be nonpolarized (HeLa, HEp-2, and
INT407) or polarized (Caco-2, HT29, and T84) cells. Polarized
cell lines have an apical surface facing the luminal side and a
basolateral side interfacing with the lamina propia and mimic
the in vivo situation. Both sides differ biochemically with re-
spect to transport functions and cellular localization of surface
components such as TLRs (11, 72, 130). The use of polarized
models is useful for studying microbial effects on transport,
transcytosis mechanisms, and cell invasion (113). Nonpolarized
models can also be used for studying bacterial virulence. Such
studies have elucidated receptors, signaling pathways, and in-
ternalization mechanisms (55, 59, 96).
Invasion assays using in vitro cell culture models allow many
parameters to be independently adjusted to achieve optimal
results. Incubation time and assay volume, which can affect the
results, are standard variables, while the number of internal-
ized bacteria strongly depends on the type of cell line and
Campylobacter strain used, the number of bacteria added per
cell, and the concentration of antibiotics used to kill noninter-
nalized bacteria (65). Although the mechanism of invasion is
currently being unraveled, the fate of internalized Campy-
lobacter, and whether they are able to replicate intracellularly,
is still unknown (for a recent review, see reference 184). More
recently, it was shown that Campylobacter was able to prevent
targeting to lysosomes in epithelial cells, whereas it was tar-
geted to lysosomes and rapidly killed by macrophages (176).
These data indicate that the invasive properties of various
Campylobacter strains are not fully understood. They also show
a considerable range in invasive abilities among strains. How-
ever, evidence on the in vitro invasive ability of a strain and the
development of disease symptoms (bacteremic/bloody diar-
rhea, etc.) has been conflicting (48, 60, 94, 120, 123) (see also
http://www.medvetnet.org/pdf/Reports/Workpackage8.pdf),
and some of the observed correlations may have been due to in
vivo passage and not virulence properties per se (123). The
toxicity of various strains has also been studied in cell culture
systems, and those studies revealed that Campylobacter-in-
duced toxicity varies from strain to strain (reviewed in refer-
ence 173).
Several studies have investigated host cell cytokine and che-
mokine responses to Campylobacter infection in cell culture
models using human epithelial or macrophage cell lines. A
number of studies showed that Campylobacter induces proin-
flammatory cytokines such as interleukin-8 (IL-8), IL-1, and
tumor necrosis factor and chemokines such as CCL2 and
CCL4 (2, 14, 88, 104). In addition, the production of Th1
cytokine gamma interferon, regulatory cytokine IL-10, and
Th2 cytokine IL-4 has been observed (2). These responses
appear to be dependent on NF-B and AP-1 activation (84,
88), although one study suggested NF-B-independent activa-
tion of proinflammatory cytokine production (88). Interest-
ingly, viable Campylobacter cells are more potent at inducing
proinflammatory cytokines than bacterial sonicates or super-
natants (2, 14), suggesting that an active Campylobacter process
is involved in these responses. Consistent with this, Campy-
lobacter mutants with a reduced ability to adhere to epithelial
cells are less potent inducers of proinflammatory responses
(82). Furthermore, Campylobacter-induced IL-8 production is
dependent on de novo protein synthesis (82, 175).
Animal Models of Infection
Murine models with defined deletions in components of
innate or adaptive immunity are crucial in identifying genetic
factors involved in the host defense against infection. However,
progress in our understanding of Campylobacter infection and
disease has been seriously hampered by the lack of an appro-
priate animal model, which makes studies in the above-men-
tioned gene-deleted mice impossible. Whereas most animals
can be colonized with Campylobacter, gastroenteritis does not
occur (reviewed in reference 122). Mice are not naturally col-
onized with Campylobacter, but in an experimental setting,
colonization can be established. Campylobacter vaccination ex-
periments have also been performed using such models, and
protection against colonization with a homologous strain could
be induced. Some authors have been able to induce gastroin-
testinal disease in infant mice (90). In these mice, intraperito-
neal injection with C. jejuni produced self-limiting diarrhea,
but since infant mice do not have a fully developed immune
system, they are not suitable for studying “normal” Campy-
lobacter disease or vaccine-induced protection. Also, in athy-
mic, germ-free, nude mice, transient diarrhea was observed
(186). Because these models display severe defects in the ca-
pacity to raise innate and adaptive immunity, they are not
suitable for measuring immune responses to Campylobacter.
For that reason, an intranasal challenge model in mice has
been developed (16). Although this is not the natural infection
route, intranasal infection of mice with Campylobacter results
in systemic disease and death of a high proportion of mice.
Various clinical isolates were differentially virulent in this
model, and also, vaccine-induced protection could be mea-
sured. However, as no diarrhea has been reported, the rele-
vance of this model for human disease is debatable, and ex-
tensive follow-up studies have not been performed.
More recently, it was shown that NF-B-deficient mice,
which have a defect in the induction of the production of
proinflammatory cytokines such as tumor necrosis factor al-
pha, IL-12, IL-1, and IL-6, develop gastroenteritis when in-
fected with Campylobacter (63). Recently, two novel murine
Campylobacter models were described, one using IL-10 gene-
deleted mice (106) and one using MyD88 gene-deleted mice
(177). The latter model, which is again a model of severely
immunocompromised mice, also revealed a role for the gene
encoding natural resistance-associated macrophage protein in
determining resistance to campylobacteriosis, suggesting that
in this model, macrophage activation and intracellular survival
may contribute to pathology (177).
Diarrheal disease in young weanling ferrets (20, 62) and in
some nonhuman primates (145) has been reported, although
few laboratories have the facilities to maintain these models. A
removable intestinal tie adult rabbit diarrhea model was also
reported (185). The model involves surgery and is of question-
able relevance to human disease, so it has not been used
extensively. Although these models can shed light on the vir-
ulence of Campylobacter and the pathogenesis of the disease,
they do not contribute to our understanding of the host factors
involved in determining susceptibility to infection. In addition,
ferret models may be complicated by the fact that ferrets are
often fed on chicks and, as a result, could be relatively resistant
to Campylobacter infection. A New World monkey Aotus nan-
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cymae model was recently reported (87), which, if it proved to
be reproducible in different laboratories and was able to dem-
onstrate colonization and invasive differences among strains,
could help to improve our understanding of C. jejuni virulence
properties and the interaction of the organism with the host.
A large amount of work has been done using chicken models
of infection. The avian gut is considered to be the natural
environment of C. jejuni. Although disease has been reported
(144), the organism is generally regarded as being a commen-
sal pathogen. Therefore, although inappropriate for determin-
ing pathogenesis mechanisms, the chicken is a suitable model
for determining colonization factors and in vivo survival mech-
anisms of thermophilic campylobacters (42). Furthermore, as
the reduction of C. jejuni numbers in poultry is seen as a way
to reduce the number of human cases (125), there have been a
number of published reports focusing on avian host factors.
Studies have characterized antibody responses to infection
(39), and in vitro studies using avian cells have identified cell-
mediated immune responses (154). Such studies have shown
that maternally derived antibodies can protect against coloni-
zation (146) and identified a genetic basis for susceptibility to
colonization (33). Those studies highlight the importance of
host factors in determining the outcome of infection. Further-
more, comparison of responses among hosts with different
pathologies and patterns of colonization can help to elucidate
pathogenesis and virulence mechanisms of the bacterium and
so aid in the development of control strategies.
Consistent with observations of patients, these studies show
that severe immune defects in mice also led to enhanced sus-
ceptibility to infection. However, research using animal models
has not yet led to the identification of clearly defined, specific
immune mechanisms that are crucial for the host defense
against Campylobacter. The recent progress in gene-deleted
mice holds promise for future studies.
Human Volunteer Studies
With the lack of an appropriate animal model for Campy-
lobacter infection, infection of human volunteers has been im-
portant in increasing our understanding of colonization and
disease induction. These studies have shown that there is a
clear dose-response relation between the number of ingested
bacteria and colonization of the patients and that Campy-
lobacter is highly infectious (23, 24). Surprisingly, no clear
dose-response relation between the number of ingested bacte-
ria and the development of clinical disease could be demon-
strated in these studies. This is in sharp contrast to the data
from a raw-milk outbreak, which showed a clear dose response,
in presumably immunologically naı¨ve children (159). However,
the volunteers in this study were not screened for preexisting
immunity to Campylobacter, and this, together with the small
study groups, may (partially) explain this finding. The two
Campylobacter strains used in these studies induced disease
with different severities, indicating that not all Campylobacter
strains have similar disease-inducing properties. After the vol-
unteers recovered, some of them were challenged with the
homologous strain, and it appeared that primary infection re-
sulted in protection against disease but not against coloniza-
tion. These data indicate that vaccination against Campy-
lobacter may be feasible, although the high level of variation
among Campylobacter strains may hamper this approach.
VACCINE-INDUCED PROTECTION
Currently, there is no vaccine against campylobacteriosis
available, but vaccination seems to be a good way to increase
basal immunity in the population. Several approaches are fol-
lowed: the development of (i) live attenuated vaccines, (ii)
vaccines based on heat-killed/formalin-killed bacteria with or
without mucosal adjuvants, (iii) subunit vaccines delivered to-
gether with adjuvants, and (iv) live attenuated Salmonella
strains expressing Campylobacter proteins. For example, recA
mutants that could be used as live attenuated vaccines have
been developed (76). Formalin- or heat-killed bacterial prep-
arations or combinations of the two have been used as oral
vaccines, with or without E. coli heat-labile toxin to enhance
mucosal responses. Such vaccine preparations were shown to
induce protective immunity in mice, ferrets, and nonhuman
primates (15, 17, 36, 141). Subunit vaccines based on FlaA
were shown to induce short-term protective immunity in mice
(100), and proteomics approaches are currently being used to
identify Campylobacter surface proteins that could be included
in subunit vaccines (137). Finally, an attenuated Salmonella
vaccine expressing Campylobacter PEB1 was shown to induce
humoral immunity in mice, with high seroconversion rates
(90% to 100%), although these responses were not protective
(150). Because of the link between Campylobacter infection
and GBS, whole-cell vaccine approaches are seriously ham-
pered. Both live and killed vaccine preparations should be
based on Campylobacter strains that cannot induce GBS. A
small study with volunteers has shown that none of the volun-
teers infected with virulent Campylobacter strains or with a
killed vaccine preparation developed persistent antiganglioside
antibodies (135). However, until we know exactly which bac-
terial and host properties are involved in the development of
GBS, large-scale vaccine trials with whole-cell vaccines are
probably not feasible.
FUTURE DIRECTIONS
What can we learn from all available information? All data
described above clearly indicate that an effective immune sys-
tem is crucial in the host defense against Campylobacter infec-
tion. However, which specific components of the host response
are important is still largely unclear. In fact, there are many
more open questions than clear answers. For instance, even
though serological responses to Campylobacter infection have
been studied and reveal that a good antibody response is es-
sential, it is still not clear whether IgG, IgA, IgM, or combi-
nations of the three are necessary.
Various approaches can be used to get answers to these
basic questions. Murine models with defined deletions in com-
ponents of innate or adaptive immunity, which have greatly
aided the identification of genetic factors involved in the host
defense against other pathogens, may yet be useful for our
understanding of Campylobacter pathogenesis. Novel develop-
ments in such animal model systems may therefore open up
possibilities for answering basic questions. Even though these
models rely on the use of severely immunocompromised mice,
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the transfer of sera and lymphocytes obtained after the infec-
tion of immunocompetent mice may be used to elucidate the
immune mechanisms involved in protection against campy-
lobacteriosis. Combined with measurement of both serum and
saliva antibodies in human infections, this approach may shed
light on this issue. This again highlights the importance of the
development of protocols which can be followed when sus-
pected outbreaks occur. Such naturally occurring events should
be exploited more effectively to advance research into host-
pathogen interactions in campylobacteriosis.
Another approach that could be taken is to perform human
genetic studies. Infectious diseases have clearly posed a strong
evolutionary pressure on the selection of immune genes. To
what extent Campylobacter infection has also played a role in
this process is unclear. Analysis of common polymorphisms in
genes involved in gastric acid production, humoral immunity,
innate immunity, and cell-mediated immunity could shed light
on the roles of various processes in the defense against Campy-
lobacter infection. However, it is also clear that it will not be so
easy to select candidate genes for such studies.
A third approach that could be taken is to allow research
into both host and pathogen factors to be much more driven by
epidemiological findings. Age-related differences in acquiring
infection with common and rare Campylobacter variants are an
example of how this could be done. One could also envisage
that similar studies can be performed with patients who do or
do not use proton pump inhibitors. This may be used to elu-
cidate whether enhanced susceptibility in these patients is re-
lated either to a higher effective dose or infection with less
virulent strains. Also, the role of other identified risk factors
for disease could be studied.
Finally, recent technical advances in host-pathogen interac-
tion research now enable detailed molecular studies into the
interaction of Campylobacter and the host. Large-scale mi-
croarray analysis can be performed either in vivo or in vitro,
and the host response to Campylobacter infection can be ana-
lyzed in detail. Proteomics approaches to study host-pathogen
interactions are also currently being developed. Such detailed
molecular studies combined with better integration of host and
pathogen research driven by epidemiological findings may
truly advance our understanding of Campylobacter infection in
humans.
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